** Drug developer Dermata Therapeutics' DRMA.O shares rise 8.2% to $1.46 premarket
** Company says its experimental drug xyngari meet primary main goal to treat moderate-to-severe acne in a late-stage study
** Main goals of the late-stage study were to measure the average change in both inflammatory and non-inflammatory skin blemishes and to assess the treatment response using a common scale called Investigator Global Assessment $(IGA)$
** Company says xyngari showed "highly statistically significant and clinically meaningful improvement" in acne compared to placebo after 12 weeks of once-weekly treatment
** Company says it is set to launch the drug in H2 2025
** As of last close, Dermata's shares down ~78% in past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。